{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(13)"],"submitter":["Bovari-Biri J"],"pubmed_abstract":["(1) Background: Tuberous sclerosis complex (TSC) mutations directly affect mTORC activity and, as a result, protein synthesis. In several cancer types, TSC mutation is part of the driver mutation panel. TSC mutations have been associated with mitochondrial dysfunction, tolerance to reactive oxygen species due to increased thioredoxin reductase (TrxR) enzyme activity, tolerance to endoplasmic reticulum (ER) stress, and apoptosis. The FDA-approved drug rapamycin is frequently used in clinical applications to inhibit protein synthesis in cancers. Recently, TrxR inhibitor auranofin has also been involved in clinical trials to investigate the anticancer efficacy of the combination treatment with rapamycin. We aimed to investigate the molecular background of the efficacy of such drug combination"],"journal":["Cells"],"pagination":["1713"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10340296"],"repository":["biostudies-literature"],"pubmed_title":["Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms."],"pmcid":["PMC10340296"],"pubmed_authors":["Bovari-Biri J","Pongracz JE","Abdelwahab EMM","Garai K"],"additional_accession":[]},"is_claimable":false,"name":"Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms.","description":"(1) Background: Tuberous sclerosis complex (TSC) mutations directly affect mTORC activity and, as a result, protein synthesis. In several cancer types, TSC mutation is part of the driver mutation panel. TSC mutations have been associated with mitochondrial dysfunction, tolerance to reactive oxygen species due to increased thioredoxin reductase (TrxR) enzyme activity, tolerance to endoplasmic reticulum (ER) stress, and apoptosis. The FDA-approved drug rapamycin is frequently used in clinical applications to inhibit protein synthesis in cancers. Recently, TrxR inhibitor auranofin has also been involved in clinical trials to investigate the anticancer efficacy of the combination treatment with rapamycin. We aimed to investigate the molecular background of the efficacy of such drug combination","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-19T15:58:43.36Z","creation":"2025-04-19T15:58:43.36Z"},"accession":"S-EPMC10340296","cross_references":{"pubmed":["37443747"],"doi":["10.3390/cells12131713"]}}